Dawn of a New Surgical Era: Micro-Robots Conquer Bladder Cancer in Human First
- Groundbreaking: Virtuoso Surgical's needle-sized robots successfully perform first-ever human bladder cancer removals.
- Revolutionary Precision: The system's sub-millimeter manipulators enable the advanced 'en bloc' tumor removal technique, drastically improving outcomes.
- New Hope: This milestone signals a transformative shift in minimally invasive surgery, promising reduced cancer recurrence for patients.
In a stunning leap forward for medical science, May 2025 marked the dawn of a new surgical age. Virtuoso Surgical, a Nashville-based pioneer, announced the first-in-human use of its Virtuoso® Surgical Robotic System, employed to successfully excise bladder cancer lesions with unprecedented precision at The Chinese University of Hong Kong (CUHK)3, 7. This isn't just an advancement; it's a revolution delivered through instruments finer than a human hair.
The Virtuoso system wields two robotically controlled, needle-sized manipulators, each less than 1 millimeter in diameter, operating from the tip of an endoscope smaller than half a U.S. dime1, 2. This patented technology, born from research at Johns Hopkins University and Vanderbilt University, gifts surgeons with almost supernatural dexterity deep within the human body1, 2. In these landmark cases, world-renowned surgeon Dr. Jeremy Teoh utilized the system to perform the delicate en bloc technique, removing tumors whole rather than piecemeal—a method proven to reduce recurrence and enhance diagnostic accuracy7, 6.
"The ability to perform an en bloc resection for bladder cancer with this level of robotic assistance is a game-changer," declared Dr. Teoh, praising the system's "exceptional maneuverability, dexterity and visual clarity." Previously, the dexterity required for en bloc made it a daunting procedure, limiting its adoption despite clear benefits7. Virtuoso shatters these limitations.
Dr. S. Duke Herrell, CEO of Virtuoso Surgical, hailed the milestone as "a testament to our team's dedication... to transform patient care." With plans for expanded trials across gynecology, neurosurgery, and more, Virtuoso is not just refining surgery; it's reimagining it5. This is more than a new tool; it's the promise of less invasive, more accurate procedures, forging a healthier future for patients worldwide.
The Virtuoso system is not FDA-approved and is not for sale in the United States. This study was done under CUHK Ethics Board approval.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.